The biomarkers (Appl1, Sortilin and Syndecan-1) are applicable across the entire biological continuum of prostate diseases from normal, to atypical hyperplasia, to PIN (prostatic intraepithelial neoplasia) to localized and metastatic carcinoma [18,27,28]. This evidence concerns the gene SORT1 and prostate intraepithelial neoplasia.